First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Scholar Rock Holding Corporation

    SRRK · 8 developments mapped · last assessed 2026-09-14

    Market Ontology has mapped 8 macro, policy, and market developments to Scholar Rock Holding Corporation since 2026-09-12. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for SRRK yet, so no modelled value is shown. The SRRK valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run SRRK on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for SRRK. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy

      Direct commercialization of a novel therapeutic, market entry into a high-value rare disease segment.

      · Moves peak sales estimates for isembyld, probability of success for pipeline assets (de risking), cost of goods sold for isembyld

    What changed, by assumption

    Peak sales estimates for isembyld
    • 2026-09-14FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
    • 2026-09-12FDA Approves Isembyld for Spinal Muscular Atrophy
    • 2026-09-12FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapy
    Probability of success for lead asset
    • 2026-09-14FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMA
    • 2026-09-13FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
    • 2026-09-12FDA approves Scholar Rock's Isembyld for spinal muscular atrophy
    Probability of success for isembyld
    • 2026-09-13FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted SMA Therapy
    Probability of success
    • 2026-09-12FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMA

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-08-06Valuation multipleBearishIncremental float typically compresses near-term multiple absent revenue acceleration.0.70
    2026-08-06Share countBullishPrimary equity issuance increases diluted share count.0.70

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-14FDA Approves Scholar Rock's Isembyld for Spinal Muscular AtrophyBullish1-3m0.90
    2026-09-14FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMABullish1-3m0.90
    2026-09-13FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted SMA TherapyBullish1-3m0.90
    2026-09-13FDA Approves Scholar Rock's Isembyld for Spinal Muscular AtrophyBullish1-3m0.90
    2026-09-12FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMABullish1-3m0.90
    2026-09-12FDA Approves Isembyld for Spinal Muscular AtrophyBullish1-3m0.90
    2026-09-12FDA approves Scholar Rock's Isembyld as first muscle-targeted SMA therapyBullish1-5y0.90
    2026-09-12FDA approves Scholar Rock's Isembyld for spinal muscular atrophyBullish1-3m0.90